This Article Full Text (PDF) Other Versions of this Article: AAC.00763-06v1 50/12/4027    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by VERA-CABRERA, L. Articles by MOLINA-TORRES, C. A. Search for Related Content PubMed PubMed Citation Articles by VERA-CABRERA, L. Articles by MOLINA-TORRES, C. A.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.00763-06
Copyright (c) 2006, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

In Vitro Activity of the Novel Oxazolidinones, DA-7867 and DA-7157, against Rapidly and Slowly Growing Mycobacteria

Servicio de Dermatología, Hospital Universitario "José E. González", Monterrey, N.L., México, Department of Microbiology, The University of Texas Health Center, Tyler, Texas, and Research Laboratory, Dong-A Pharmaceutical Co., Ltd., Yongin, Korea

^* To whom correspondence should be addressed. Email: luvera_99{at}yahoo.com,

	Abstract

DA-7867 and DA-7157 are oxazolidinones active against pathogenic aerobic actinomycetes including Nocardia spp and Mycobacterium tuberculosis. However the activity of these drugs against non-tuberculous mycobacterium (NTM) species is not known. In this work we compared the susceptibility of 122 clinical isolates and 29 reference species of both rapidly growing and slowly growing mycobacteria to linezolid, DA-7867 and DA-7157 using the broth microdilution method. MIC₅₀ and MIC₉₀ values of DA-7867 and DA-7157 were lower than those of linezolid. In all the cases an MIC₉₀ value of <8 µg/ml was observed for all the species tested in both groups of NTM. M. kansasii and M. marinum isolates exhibited MIC₉₀ values of less than 0.5 µg/ml for both, DA-7867 and DA-7157. These results demonstrate the potential of these compounds to treat NTM infections.